EHI
Eagle Health Investments Portfolio holdings
AUM
$405M
This Quarter Return
+15.13%
1 Year Return
+14.19%
3 Year Return
+134.25%
5 Year Return
–
10 Year Return
–
AUM
$519M
AUM Growth
+$519M
(-7.3%)
Cap. Flow
-$103M
Cap. Flow
% of AUM
-19.95%
Top 10 Holdings %
Top 10 Hldgs %
72.99%
Holding
27
New
1
Increased
4
Reduced
8
Closed
2
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$14.8M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
$13.2M |
| 3 |
DexCom
DXCM
|
$11.8M |
| 4 |
Illumina
ILMN
|
$8.95M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
$2.07M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$40.6M |
| 2 |
IQVIA
IQV
|
$25.8M |
| 3 |
UnitedHealth
UNH
|
$21.2M |
| 4 |
Guardant Health
GH
|
$18.1M |
| 5 |
Transmedics
TMDX
|
$18M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $54.8M | 10.37% | 431,314 -42,800 | -9% | -$5.43M |
|
|
2
Illumina
ILMN
$15.8B
| $50.5M | 9.57% | 387,354 +68,600 | +22% | +$8.95M |
|
3
argenx
ARGX
$43.6B
| $40.7M | 7.7% | 74,990 -13,900 | -16% | -$7.53M |
|
4
Icon
ICLR
$13.8B
| $37.6M | 7.12% | 130,790 -18,800 | -13% | -$5.4M |
|
5
Insmed
INSM
$28.8B
| $37.5M | 7.1% | 513,700 | – | – |
|
6
Exact Sciences
EXAS
$8.98B
| $37.1M | 7.02% | 544,200 | – | – |
|
|
7
Ultragenyx Pharmaceutical
RARE
$2.89B
| $31.2M | 5.91% | 561,700 +37,200 | +7% | +$2.07M |
|
|
8
DexCom
DXCM
$29.5B
| $30.3M | 5.73% | 451,492 +175,774 | +64% | +$11.8M |
|
|
9
UnitedHealth
UNH
$281B
| $29.6M | 5.61% | 50,700 -36,200 | -42% | -$21.2M |
|
|
10
BioMarin Pharmaceuticals
BMRN
$11.2B
| $29.5M | 5.58% | 419,212 +187,412 | +81% | +$13.2M |
|
11
Inspire Medical Systems
INSP
$2.77B
| $28.8M | 5.46% | 136,603 | – | – |
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $21M | 3.97% | 76,256 | – | – |
|
|
13
United Therapeutics
UTHR
$13.8B
| $19.4M | 3.67% | 54,099 -113,400 | -68% | -$40.6M |
|
14
Procept Biorobotics
PRCT
$2.23B
| $18.7M | 3.54% | 233,089 -24,000 | -9% | -$1.92M |
|
|
15
Neurocrine Biosciences
NBIX
$13.8B
| $14.8M | 2.81% | +128,600 | New | +$14.8M |
|
16
Agios Pharmaceuticals
AGIO
$2.19B
| $14.7M | 2.78% | 330,830 | – | – |
|
17
4D Molecular Therapeutics
FDMT
$288M
| $5M | 0.95% | 462,911 | – | – |
|
18
Lantheus
LNTH
$3.73B
| $4.74M | 0.9% | 43,200 | – | – |
|
19
Intuitive Surgical
ISRG
$170B
| $3.63M | 0.69% | 7,390 -20,900 | -74% | -$10.3M |
|
20
Viking Therapeutics
VKTX
$3.04B
| $2.85M | 0.54% | 45,000 | – | – |
|
|
21
Transmedics
TMDX
$3.92B
| $2.84M | 0.54% | 18,061 -114,800 | -86% | -$18M |
|
22
Werewolf Therapeutics
HOWL
$59.9M
| $1.48M | 0.28% | 700,000 | – | – |
|
23
Immunocore
IMCR
$1.62B
| $1.44M | 0.27% | 46,300 | – | – |
|
|
GRAL
24
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $731K | 0.14% | 53,124 | – | – |
|
25
CRISPR Therapeutics
CRSP
$4.71B
| – | – | 0 | – | – |
|